

Maria Elena Bottazzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6428906/publications.pdf>

Version: 2024-02-01

212
papers

10,742
citations

30070

54
h-index

43889

91
g-index

228
all docs

228
docs citations

228
times ranked

12379
citing authors

#	ARTICLE	IF	CITATIONS
1	The Neglected Tropical Diseases of Latin America and the Caribbean: A Review of Disease Burden and Distribution and a Roadmap for Control and Elimination. PLoS Neglected Tropical Diseases, 2008, 2, e300.	3.0	562
2	Hookworm Infection. New England Journal of Medicine, 2004, 351, 799-807.	27.0	556
3	Global economic burden of Chagas disease: a computational simulation model. Lancet Infectious Diseases, The, 2013, 13, 342-348.	9.1	490
4	The SARS-CoV-2 Vaccine Pipeline: an Overview. Current Tropical Medicine Reports, 2020, 7, 61-64.	3.7	403
5	Vaccine Efficacy Needed for a COVID-19 Coronavirus Vaccine to Prevent or Stop an Epidemic as the Sole Intervention. American Journal of Preventive Medicine, 2020, 59, 493-503.	3.0	259
6	Disproportionate impact of the COVID-19 pandemic on immigrant communities in the United States. PLoS Neglected Tropical Diseases, 2020, 14, e0008484.	3.0	256
7	Î±5Î²1 Integrin Controls Cyclin D1 Expression by Sustaining Mitogen-activated Protein Kinase Activity in Growth Factor-treated Cells. Molecular Biology of the Cell, 1999, 10, 3197-3204.	2.1	200
8	Chagas Disease: "The New HIV/AIDS of the Americas" PLoS Neglected Tropical Diseases, 2012, 6, e1498.	3.0	184
9	Status of vaccine research and development of vaccines for leishmaniasis. Vaccine, 2016, 34, 2992-2995.	3.8	176
10	Antibodies against a secreted protein from hookworm larvae reduce the intensity of hookworm infection in humans and vaccinated laboratory animals. FASEB Journal, 2005, 19, 1743-1745.	0.5	169
11	Hookworm: "The Great Infection of Mankind" PLoS Medicine, 2005, 2, e67.	8.4	164
12	COVID-19 vaccine design: the Janus face of immune enhancement. Nature Reviews Immunology, 2020, 20, 347-348.	22.7	155
13	Progress in the development of a recombinant vaccine for human hookworm disease: The Human Hookworm Vaccine Initiative. International Journal for Parasitology, 2003, 33, 1245-1258.	3.1	137
14	Regulation of P21cip1 Expression by Growth Factors and the Extracellular Matrix Reveals a Role for Transient ERK Activity in G1 Phase. Journal of Cell Biology, 1999, 146, 1255-1264.	5.2	126
15	Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Review of Vaccines, 2012, 11, 1405-1413.	4.4	126
16	New vaccines for neglected parasitic diseases and dengue. Translational Research, 2013, 162, 144-155.	5.0	126
17	Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19. Human Vaccines and Immunotherapeutics, 2020, 16, 1239-1242.	3.3	120
18	Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects. Expert Review of Vaccines, 2012, 11, 1043-1055.	4.4	117

#	ARTICLE	IF	CITATIONS
19	Lancet COVID-19 Commission Statement on the occasion of the 75th session of the UN General Assembly. Lancet, The, 2020, 396, 1102-1124.	13.7	117
20	Vaccination with Recombinant Aspartic Hemoglobinase Reduces Parasite Load and Blood Loss after Hookworm Infection in Dogs. PLoS Medicine, 2005, 2, e295.	8.4	115
21	An Unfolding Tragedy of Chagas Disease in North America. PLoS Neglected Tropical Diseases, 2013, 7, e2300.	3.0	114
22	Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Human Vaccines and Immunotherapeutics, 2014, 10, 648-658.	3.3	112
23	The BENEFIT Trial: Where Do We Go from Here?. PLoS Neglected Tropical Diseases, 2016, 10, e0004343.	3.0	112
24	The Global Economic and Health Burden of Human Hookworm Infection. PLoS Neglected Tropical Diseases, 2016, 10, e0004922.	3.0	111
25	Human Intestinal Parasite Burden and Poor Sanitation in Rural Alabama. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1623-1628.	1.4	107
26	The Human Hookworm Vaccine. Vaccine, 2013, 31, B227-B232.	3.8	105
27	Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics. Lancet, The, 2021, 397, 562-564.	13.7	105
28	The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement. Microbes and Infection, 2020, 22, 165-167.	1.9	103
29	The HTLV-I Tax oncoprotein targets the retinoblastoma protein for proteasomal degradation. Oncogene, 2005, 24, 525-540.	5.9	100
30	Vaccination of Dogs with a Recombinant Cysteine Protease from the Intestine of Canine Hookworms Diminishes the Fecundity and Growth of Worms. Journal of Infectious Diseases, 2004, 189, 1952-1961.	4.0	98
31	Ancylostoma caninum MTP-1, an Astacin-Like Metalloprotease Secreted by Infective Hookworm Larvae, Is Involved in Tissue Migration. Infection and Immunity, 2006, 74, 961-967.	2.2	98
32	Neglected Tropical Diseases among the Association of Southeast Asian Nations (ASEAN): Overview and Update. PLoS Neglected Tropical Diseases, 2015, 9, e0003575.	3.0	97
33	Optimization of the Production Process and Characterization of the Yeast-Expressed SARS-CoV Recombinant Receptor-Binding Domain (RBD219-N1), a SARS Vaccine Candidate. Journal of Pharmaceutical Sciences, 2017, 106, 1961-1970.	3.3	95
34	Advancing a vaccine to prevent human schistosomiasis. Vaccine, 2016, 34, 2988-2991.	3.8	90
35	Molecular Cloning, Biochemical Characterization, and Partial Protective Immunity of the Heme-Binding Glutathione <i>S</i> -Transferases from the Human Hookworm <i>Necator americanus</i> . Infection and Immunity, 2010, 78, 1552-1563.	2.2	89
36	Expression of the <i>Necator americanus</i> hookworm larval antigen Na-ASP-2 in <i>Pichia pastoris</i> and purification of the recombinant protein for use in human clinical trials. Vaccine, 2005, 23, 4754-4764.	3.8	88

#	ARTICLE	IF	CITATIONS
37	Toxocariasis in North America: A Systematic Review. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3116.	3.0	88
38	New technologies for the control of human hookworm infection. <i>Trends in Parasitology</i> , 2006, 22, 327-331.	3.3	84
39	Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. <i>Vaccine</i> , 2020, 38, 7533-7541.	3.8	84
40	An enzymatically inactivated hemoglobinase from <i>Necator americanus</i> induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection. <i>FASEB Journal</i> , 2009, 23, 3007-3019.	0.5	83
41	Protein Profile of Tax-associated Complexes. <i>Journal of Biological Chemistry</i> , 2004, 279, 495-508.	3.4	79
42	Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 145-157.	4.4	77
43	COVID-19 vaccines: neutralizing antibodies and the alum advantage. <i>Nature Reviews Immunology</i> , 2020, 20, 399-400.	22.7	74
44	Operation Warp Speed: implications for global vaccine security. <i>The Lancet Global Health</i> , 2021, 9, e1017-e1021.	6.3	72
45	Developing a low-cost and accessible COVID-19 vaccine for global health. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008548.	3.0	66
46	Advancing a multivalent "Pan-anthelmintic" vaccine against soil-transmitted nematode infections. <i>Expert Review of Vaccines</i> , 2014, 13, 321-331.	4.4	65
47	SARS-CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2356-2366.	3.3	64
48	Correcting COVID-19 vaccine misinformation. <i>EClinicalMedicine</i> , 2021, 33, 100780.	7.1	63
49	Modeling the economic value of a Chagas disease therapeutic vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1293-1301.	3.3	62
50	Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. <i>Vaccine</i> , 2018, 36, 1853-1862.	3.8	62
51	Role of viral regulatory and accessory proteins in HIV-1 replication. <i>Frontiers in Bioscience - Landmark</i> , 2004, 9, 2388.	3.0	61
52	Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005574.	3.0	60
53	Vaccination with irradiated <i>Ancylostoma caninum</i> third stage larvae induces a Th2 protective response in dogs. <i>Vaccine</i> , 2006, 24, 501-509.	3.8	57
54	Neglected tropical diseases in Central America and Panama: Review of their prevalence, populations at risk and impact on regional development. <i>International Journal for Parasitology</i> , 2014, 44, 597-603.	3.1	57

#	ARTICLE	IF	CITATIONS
55	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. <i>Science Translational Medicine</i> , 2022, 14, .	12.4	57
56	Status of vaccine research and development of vaccines for Chagas disease. <i>Vaccine</i> , 2016, 34, 2996-3000.	3.8	56
57	Whole Inactivated Virus and Protein-Based COVID-19 Vaccines. <i>Annual Review of Medicine</i> , 2022, 73, 55-64.	12.2	55
58	A yeast-expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates. <i>Science Immunology</i> , 2021, 6, .	11.9	53
59	A therapeutic nanoparticle vaccine against <i>Trypanosoma cruzi</i> in a BALB/c mouse model of Chagas disease. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 976-987.	3.3	52
60	New Vaccines for the World's Poorest People. <i>Annual Review of Medicine</i> , 2016, 67, 405-417.	12.2	52
61	The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas. <i>Vaccine</i> , 2013, 31, 480-486.	3.8	51
62	The role of cyclin D2 and p21/waf1 in human T-cell leukemia virus type 1 infected cells. <i>Retrovirology</i> , 2004, 1, 6.	2.0	49
63	Human anthelmintic vaccines: Rationale and challenges. <i>Vaccine</i> , 2016, 34, 3549-3555.	3.8	49
64	Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2021, 1865, 129893.	2.4	49
65	Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease. <i>Infection and Immunity</i> , 2018, 86, .	2.2	47
66	Texas and Mexico: Sharing a Legacy of Poverty and Neglected Tropical Diseases. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1497.	3.0	47
67	Expression, Immunogenicity, Histopathology, and Potency of a Mosquito-Based Malaria Transmission-Blocking Recombinant Vaccine. <i>Infection and Immunity</i> , 2012, 80, 1606-1614.	2.2	46
68	Innovation for the "Bottom 100 Million": Eliminating Neglected Tropical Diseases in the Americas. <i>Advances in Experimental Medicine and Biology</i> , 2013, 764, 1-12.	1.6	45
69	Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic. <i>EClinicalMedicine</i> , 2021, 39, 101053.	7.1	45
70	Functional consequences of cyclin D1/BRCA1 interaction in breast cancer cells. <i>Oncogene</i> , 2007, 26, 5060-5069.	5.9	42
71	Identification of vaccine targets in pathogens and design of a vaccine using computational approaches. <i>Scientific Reports</i> , 2021, 11, 17626.	3.3	42
72	Expression, purification, immunogenicity, and protective efficacy of a recombinant Tc24 antigen as a vaccine against <i>Trypanosoma cruzi</i> infection in mice. <i>Vaccine</i> , 2015, 33, 4505-4512.	3.8	41

#	ARTICLE	IF	CITATIONS
73	Lessons along the Critical Path: Developing Vaccines against Human Helminths. Trends in Parasitology, 2018, 34, 747-758.	3.3	41
74	Advancing the Development of a Human Schistosomiasis Vaccine. Trends in Parasitology, 2019, 35, 104-108.	3.3	41
75	Maintaining face mask use before and after achieving different COVID-19 vaccination coverage levels: a modelling study. Lancet Public Health, The, 2022, 7, e356-e365.	10.0	41
76	A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic <i>Trypanosoma cruzi</i> infection. PLoS Neglected Tropical Diseases, 2019, 13, e0007413.	3.0	40
77	Cysteine mutagenesis improves the production without abrogating antigenicity of a recombinant protein vaccine candidate for human chagas disease. Human Vaccines and Immunotherapeutics, 2017, 13, 621-633.	3.3	39
78	Controlled Human Hookworm Infection: Accelerating Human Hookworm Vaccine Development. Open Forum Infectious Diseases, 2018, 5, ofy083.	0.9	37
79	A method to probe protein structure from UV absorbance spectra. Analytical Biochemistry, 2019, 587, 113450.	2.4	37
80	Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1. Applied Microbiology and Biotechnology, 2021, 105, 4153-4165.	3.6	37
81	Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with <i>Onchocerca volvulus</i> in a mouse model. International Journal for Parasitology, 2014, 44, 637-646.	3.1	36
82	Advancing a vaccine to prevent hookworm disease and anemia. Vaccine, 2016, 34, 3001-3005.	3.8	36
83	<i>Onchocerca volvulus</i> : The Road from Basic Biology to a Vaccine. Trends in Parasitology, 2018, 34, 64-79.	3.3	36
84	IgG Induced by Vaccination With <i>Ascaris suum</i> Extracts Is Protective Against Infection. Frontiers in Immunology, 2018, 9, 2535.	4.8	36
85	Optimization and revision of the production process of the <i>Necator americanus</i> glutathione S-transferase 1 (<i>Nc</i> -GST-1), the lead hookworm vaccine recombinant protein candidate. Human Vaccines and Immunotherapeutics, 2014, 10, 1914-1925.	3.3	35
86	Expression, purification, and characterization of the <i>Necator americanus</i> aspartic protease-1 (<i>Nc</i> -APR-1 (M74)) antigen, a component of the bivalent human hookworm vaccine. Human Vaccines and Immunotherapeutics, 2015, 11, 1474-1488.	3.3	35
87	The Onchocerciasis Vaccine for Africa "TOVA" Initiative. PLoS Neglected Tropical Diseases, 2015, 9, e0003422.	3.0	35
88	Expression at a 20L scale and purification of the extracellular domain of the <i>Schistosoma mansoni</i> TSP-2 recombinant protein. Human Vaccines and Immunotherapeutics, 2013, 9, 2342-2350.	3.3	33
89	Modeling the economic and epidemiologic impact of hookworm vaccine and mass drug administration (MDA) in Brazil, a high transmission setting. Vaccine, 2016, 34, 2197-2206.	3.8	33
90	Production of recombinant TSA-1 and evaluation of its potential for the immuno-therapeutic control of <i>Trypanosoma cruzi</i> infection in mice. Human Vaccines and Immunotherapeutics, 2019, 15, 210-219.	3.3	33

#	ARTICLE	IF	CITATIONS
91	The silent and dangerous inequity around access to COVID-19 testing: A call to action. <i>EClinicalMedicine</i> , 2022, 43, 101230.	7.1	33
92	Lives and Costs Saved by Expanding and Expediting Coronavirus Disease 2019 Vaccination. <i>Journal of Infectious Diseases</i> , 2021, 224, 938-948.	4.0	32
93	Expression, purification, and molecular analysis of the <i>Necator americanus</i> glutathione S-transferase 1 (Na-GST-1): A production process developed for a lead candidate recombinant hookworm vaccine antigen. <i>Protein Expression and Purification</i> , 2012, 83, 145-151.	1.3	31
94	Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B supertypes in Chagasic chronic patients from Mexico. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006240.	3.0	31
95	Development of Chagas Cardiac Manifestations Among Texas Blood Donors. <i>American Journal of Cardiology</i> , 2015, 115, 113-117.	1.6	30
96	Yeast-expressed recombinant As16 protects mice against <i>Ascaris suum</i> infection through induction of a Th2-skewed immune response. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005769.	3.0	30
97	<i>Ascaris</i> Larval Infection and Lung Invasion Directly Induce Severe Allergic Airway Disease in Mice. <i>Infection and Immunity</i> , 2018, 86, .	2.2	30
98	Potency testing for the experimental <i>Na-GST-1</i> hookworm vaccine. <i>Expert Review of Vaccines</i> , 2010, 9, 1219-1230.	4.4	29
99	Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens. <i>Vaccines</i> , 2019, 7, 131.	4.4	29
100	Distinct Effects of Mitogens and the Actin Cytoskeleton on CREB and Pocket Protein Phosphorylation Control the Extent and Timing of Cyclin A Promoter Activity. <i>Molecular and Cellular Biology</i> , 2001, 21, 7607-7616.	2.3	28
101	The Unfinished Public Health Agenda of Chagas Disease in the Era of Globalization. <i>PLoS Neglected Tropical Diseases</i> , 2009, 3, e470.	3.0	28
102	The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine. <i>American Journal of Preventive Medicine</i> , 2021, 60, 605-613.	3.0	28
103	The Impact of Concurrent and Treated <i>Ancylostoma ceylanicum</i> Hookworm Infections on the Immunogenicity of a Recombinant Hookworm Vaccine in Hamsters. <i>Journal of Infectious Diseases</i> , 2006, 193, 155-162.	4.0	27
104	Reduction of Worm Fecundity and Canine Host Blood Loss Mediates Protection against Hookworm Infection Elicited by Vaccination with Recombinant Ac- 16. <i>Vaccine Journal</i> , 2007, 14, 281-287.	3.1	27
105	<i>Trypanosoma cruzi</i> screening in Texas blood donors, 2008-2012. <i>Epidemiology and Infection</i> , 2016, 144, 1010-1013.	2.1	27
106	<i>Schistosoma haematobium</i> Extracellular Vesicle Proteins Confer Protection in a Heterologous Model of Schistosomiasis. <i>Vaccines</i> , 2020, 8, 416.	4.4	27
107	Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 275-285.	9.1	27
108	The human hookworm vaccine: recent updates and prospects for success. <i>Journal of Helminthology</i> , 2015, 89, 540-544.	1.0	26

#	ARTICLE	IF	CITATIONS
109	Host Immunity and Inflammation to Pulmonary Helminth Infections. <i>Frontiers in Immunology</i> , 2020, 11, 594520.	4.8	26
110	Priorities for the COVID-19 pandemic at the start of 2021: statement of the Lancet COVID-19 Commission. <i>Lancet, The</i> , 2021, 397, 947-950.	13.7	26
111	Vaccination of Gerbils with Bm-103 and Bm-RAL-2 Concurrently or as a Fusion Protein Confers Consistent and Improved Protection against <i>Brugia malayi</i> Infection. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004586.	3.0	25
112	Global COVID-19 Efforts as the Platform to Achieving the Sustainable Development Goals. <i>Current Tropical Medicine Reports</i> , 2020, 7, 99-103.	3.7	25
113	Protective immunity elicited by the nematode-conserved As37 recombinant protein against <i>Ascaris suum</i> infection. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008057.	3.0	25
114	Repeat-Driven Generation of Antigenic Diversity in a Major Human Pathogen, <i>Trypanosoma cruzi</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 614665.	3.9	25
115	A novel blood-feeding detoxification pathway in <i>Nippostrongylus brasiliensis</i> L3 reveals a potential checkpoint for arresting hookworm development. <i>PLoS Pathogens</i> , 2018, 14, e1006931.	4.7	24
116	Calling for rapid development of a safe and effective MERS vaccine. <i>Microbes and Infection</i> , 2014, 16, 529-531.	1.9	23
117	Characterization and Stability of <i>Trypanosoma cruzi</i> Tc24-C4 (Tc24-C4), a Candidate Antigen for a Therapeutic Vaccine Against Chagas Disease. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1468-1473.	3.3	23
118	“Running the Gauntlet”: Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a “Call to Action”. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2235-2242.	3.3	22
119	Central Latin America: Two decades of challenges in neglected tropical disease control. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0007962.	3.0	22
120	Will COVID-19 become the next neglected tropical disease?. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008271.	3.0	22
121	An ounce of prevention on a budget: a nonprofit approach to developing vaccines against neglected diseases. <i>Expert Review of Vaccines</i> , 2006, 5, 189-198.	4.4	21
122	Biophysical and Stabilization Studies of the <i>Chlamydia trachomatis</i> Mouse Pneumonitis Major Outer Membrane Protein. <i>Molecular Pharmaceutics</i> , 2009, 6, 1553-1561.	4.6	21
123	Improved Biomarker and Imaging Analysis for Characterizing Progressive Cardiac Fibrosis in a Mouse Model of Chronic Chagasic Cardiomyopathy. <i>Journal of the American Heart Association</i> , 2019, 8, e013365.	3.7	21
124	Yeast-expressed recombinant SARS-CoV-2 receptor binding domain RBD203-N1 as a COVID-19 protein vaccine candidate. <i>Protein Expression and Purification</i> , 2022, 190, 106003.	1.3	21
125	Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern. <i>Vaccine</i> , 2022, 40, 3655-3663.	3.8	21
126	A Scoping Review and Prevalence Analysis of Soil-Transmitted Helminth Infections in Honduras. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e2653.	3.0	20

#	ARTICLE	IF	CITATIONS
127	Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute <i>Trypanosoma cruzi</i> infection. <i>Scientific Reports</i> , 2021, 11, 3222.	3.3	20
128	The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against <i>Onchocerca volvulus</i> in Mice. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004797.	3.0	20
129	Identification of immunodominant antigens for the laboratory diagnosis of toxocariasis. <i>Tropical Medicine and International Health</i> , 2015, 20, 1787-1796.	2.3	19
130	The hookworm <i>Ancylostoma ceylanicum</i> intestinal transcriptome provides a platform for selecting drug and vaccine candidates. <i>Parasites and Vectors</i> , 2016, 9, 518.	2.5	19
131	Ac-AP-12, a novel factor Xa anticoagulant peptide from the esophageal glands of adult <i>Ancylostoma caninum</i> . <i>Molecular and Biochemical Parasitology</i> , 2011, 177, 42-48.	1.1	18
132	<i>Trichuris muris</i> whey acidic protein induces type 2 protective immunity against whipworm. <i>PLoS Pathogens</i> , 2018, 14, e1007273.	4.7	18
133	Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to <i>Onchocerca volvulus</i> infection in both mice and humans. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007730.	3.0	18
134	Mechanisms of HTLV-1 transformation. <i>Frontiers in Bioscience - Landmark</i> , 2004, 9, 2347.	3.0	17
135	Biophysical and formulation studies of the <i>Schistosoma mansoni</i> TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2351-2361.	3.3	17
136	Alterations to the Cardiac Metabolome Induced by Chronic <i>T. cruzi</i> Infection Relate to the Degree of Cardiac Pathology. <i>ACS Infectious Diseases</i> , 2021, 7, 1638-1649.	3.8	17
137	Model for product development of vaccines against neglected tropical diseases: a vaccine against human hookworm. <i>Expert Review of Vaccines</i> , 2008, 7, 1481-1492.	4.4	16
138	Genetic Adjuvantation of a Cell-Based Therapeutic Vaccine for Amelioration of Chagasic Cardiomyopathy. <i>Infection and Immunity</i> , 2017, 85, .	2.2	16
139	Ligand binding properties of two <i>Brugia malayi</i> fatty acid and retinol (FAR) binding proteins and their vaccine efficacies against challenge infection in gerbils. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006772.	3.0	16
140	Safety and immunogenicity of a recombinant vaccine against <i>Trypanosoma cruzi</i> in Rhesus macaques. <i>Vaccine</i> , 2020, 38, 4584-4591.	3.8	16
141	Immunogenicity of the Hookworm Na-ASP-2 Vaccine Candidate: Characterization of Humoral and Cellular Responses after Vaccination in the Sprague Dawley Rat. <i>Hum Vaccin</i> , 2005, 1, 123-128.	2.4	15
142	New tools for NTD vaccines: A case study of quality control assays for product development of the human hookworm vaccine Na-APR-1M74. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1251-1257.	3.3	15
143	Coronavirus vaccine-associated lung immunopathology-what is the significance?. <i>Microbes and Infection</i> , 2020, 22, 403-404.	1.9	15
144	TLR4 agonist protects against <i>Trypanosoma cruzi</i> acute lethal infection by decreasing cardiac parasite burdens. <i>Parasite Immunology</i> , 2020, 42, e12769.	1.5	14

#	ARTICLE	IF	CITATIONS
145	Vaccination with chimeric protein induces protection in murine model against ascariasis. <i>Vaccine</i> , 2021, 39, 394-401.	3.8	14
146	Immunomics-guided discovery of serum and urine antibodies for diagnosing urogenital schistosomiasis: a biomarker identification study. <i>Lancet Microbe</i> , The, 2021, 2, e617-e626.	7.3	14
147	Advances in vaccines against neglected tropical diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 765-776.	3.3	13
148	The Factor H-Binding Site of CspZ as a Protective Target against Multistrain, Tick-Transmitted Lyme Disease. <i>Infection and Immunity</i> , 2020, 88, .	2.2	13
149	Expression and purification of an engineered, yeast-expressed <i>Leishmania donovani</i> nucleoside hydrolase with immunogenic properties. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1-14.	3.3	12
150	Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. <i>Vaccine</i> , 2019, 37, 3704-3714.	3.8	12
151	Advances in neglected tropical disease vaccines: Developing relative potency and functional assays for the Na-GST-1/Alhydrogel hookworm vaccine. <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005385.	3.0	12
152	Expression of the c- <i>ski</i> Proto-Oncogene During Cell Cycle Arrest and Myogenic Differentiation. <i>DNA and Cell Biology</i> , 1995, 14, 701-707.	1.9	11
153	Identification and Characterization of the <i>Trypanosoma cruzi</i> B-cell Superantigen Tc24. <i>American Journal of Tropical Medicine and Hygiene</i> , 2016, 94, 114-121.	1.4	11
154	Expression, purification, immunogenicity and protective efficacy of a recombinant nucleoside hydrolase from <i>Leishmania donovani</i> , a vaccine candidate for preventing cutaneous leishmaniasis. <i>Protein Expression and Purification</i> , 2017, 130, 129-136.	1.3	11
155	Structure of SALO, a leishmaniasis vaccine candidate from the sand fly <i>Lutzomyia longipalpis</i> . <i>PLoS Neglected Tropical Diseases</i> , 2017, 11, e0005374.	3.0	11
156	China's shifting neglected parasitic infections in an era of economic reform, urbanization, disease control, and the Belt and Road Initiative. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0006946.	3.0	11
157	Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment. <i>EclinicalMedicine</i> , 2021, 36, 100925.	7.1	11
158	<i>Onchocerca volvulus</i> bivalent subunit vaccine induces protective immunity in genetically diverse collaborative cross recombinant inbred intercross mice. <i>Npj Vaccines</i> , 2021, 6, 17.	6.0	11
159	Ears of the Armadillo: Global Health Research and Neglected Diseases in Texas. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2021.	3.0	10
160	Identification, Characterization, and Structure of Tm16 from <i>Trichuris muris</i> . <i>Journal of Parasitology Research</i> , 2017, 2017, 1-10.	1.2	10
161	COVID-19 in the Americas and the erosion of human rights for the poor. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008954.	3.0	10
162	Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE Adjuvant. <i>Microorganisms</i> , 2021, 9, 2253.	3.6	10

#	ARTICLE	IF	CITATIONS
163	Transient <i>Ascaris suum</i> larval migration induces intractable chronic pulmonary disease and anemia in mice. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0010050.	3.0	10
164	Preparing for SARS-CoV-2 Vaccines in US Immigrant Communities: Strategies for Allocation, Distribution, and Communication. <i>American Journal of Public Health</i> , 2021, 111, 577-581.	2.7	9
165	Signal Transducer and Activator of Transcription-3 Modulation of Cardiac Pathology in Chronic Chagasic Cardiomyopathy. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 708325.	3.9	9
166	Location and expression kinetics of Tc24 in different life stages of <i>Trypanosoma cruzi</i> . <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009689.	3.0	9
167	Use of Multi-Parallel Real-Time Quantitative PCR to Determine Blastocystis Prevalence and Association with Other Gastrointestinal Parasite Infection in a Rural Honduran Location. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 102, 1373-1375.	1.4	9
168	Process Characterization and Biophysical Analysis for a Yeast-Expressed <i>Phlebotomus papatasi</i> Salivary Protein (PpSP15) as a <i>Leishmania</i> Vaccine Candidate. <i>Journal of Pharmaceutical Sciences</i> , 2020, 109, 1673-1680.	3.3	8
169	A new patient registry for Chagas disease. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008418.	3.0	8
170	In vitro cultured peripheral blood mononuclear cells from patients with chronic schistosomiasis <i>mansoni</i> show immunomodulation of cyclin D1,2,3 in the presence of soluble egg antigens. <i>Microbes and Infection</i> , 2007, 9, 1493-1499.	1.9	7
171	Limited antigenic variation in the <i>Trypanosoma cruzi</i> candidate vaccine antigen TSA. <i>Parasite Immunology</i> , 2014, 36, 708-712.	1.5	7
172	The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4 + T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway. <i>Vaccine</i> , 2018, 36, 3650-3665.	3.8	7
173	The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission. <i>Vaccine</i> , 2020, 38, 3261-3270.	3.8	7
174	Urgent needs to accelerate the race for COVID-19 therapeutics. <i>EClinicalMedicine</i> , 2021, 36, 100911.	7.1	7
175	Achieving global equity for COVID-19 vaccines: Stronger international partnerships and greater advocacy and solidarity are needed. <i>PLoS Medicine</i> , 2021, 18, e1003772.	8.4	7
176	Biochemical Screening of Potent Zika Virus Protease Inhibitors. <i>ChemMedChem</i> , 2022, 17, e202100695.	3.2	7
177	Vaxi-DL: A web-based deep learning server to identify potential vaccine candidates. <i>Computers in Biology and Medicine</i> , 2022, 145, 105401.	7.0	7
178	Vaccines against neglected tropical diseases: promising interventions to rescue the poorest populations in the Americas. <i>Immunotherapy</i> , 2014, 6, 117-119.	2.0	6
179	Advances in vaccine development for human trichuriasis. <i>Parasitology</i> , 2021, , 1-12.	1.5	6
180	Characterization of T cell responses to co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in healthy adults in Gabon. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009732.	3.0	6

#	ARTICLE	IF	CITATIONS
181	A research capacity strengthening project for infectious diseases in Honduras: experience and lessons learned. <i>Global Health Action</i> , 2013, 6, 21643.	1.9	5
182	The Gulf of Mexico: A "Hot Zone" for Neglected Tropical Diseases?. <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003481.	3.0	5
183	Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With <i>Onchocerca ochengi</i> . <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 869039.	3.9	5
184	ASCVac-1, a Multi-Peptide Chimeric Vaccine, Protects Mice Against <i>Ascaris suum</i> Infection. <i>Frontiers in Immunology</i> , 2021, 12, 788185.	4.8	5
185	Co-Administration of Adjuvanted Recombinant Ov-103 and Ov-RAL-2 Vaccines Confer Protection against Natural Challenge in A Bovine <i>Onchocerca ochengi</i> Infection Model of Human Onchocerciasis. <i>Vaccines</i> , 2022, 10, 861.	4.4	5
186	Helminth Infections of Children: Prospects for Control. , 2005, 568, 135-144.		4
187	Covalent vaccination with <i>Trypanosoma cruzi</i> Tc24 induces catalytic antibody production. <i>Parasite Immunology</i> , 2018, 40, e12585.	1.5	4
188	A scalable and reproducible manufacturing process for <i>Phlebotomus papatasi</i> salivary protein PpSP15, a vaccine candidate for leishmaniasis. <i>Protein Expression and Purification</i> , 2021, 177, 105750.	1.3	4
189	Reproductive Outcomes in Rhesus Macaques (<i>Macaca mulatta</i>) with Naturally-acquired <i>Trypanosoma cruzi</i> Infection. <i>Comparative Medicine</i> , 2020, 70, 152-159.	1.0	4
190	Controlled Infection of Humans with the Hookworm Parasite <i>Necator americanus</i> to Accelerate Vaccine Development. <i>Current Topics in Microbiology and Immunology</i> , 2021, , 1.	1.1	4
191	Mucosal Vaccination With Recombinant Tm-WAP49 Protein Induces Protective Humoral and Cellular Immunity Against Experimental Trichuriasis in AKR Mice. <i>Frontiers in Immunology</i> , 2022, 13, 800295.	4.8	4
192	An aluminum hydroxide: CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. <i>Science Translational Medicine</i> , 2021, , eabj5305.	12.4	4
193	Expression, purification, crystallization and preliminary X-ray analysis of a truncated soluble domain of human glioma pathogenesis-related protein 1. <i>Acta Crystallographica Section F: Structural Biology Communications</i> , 2010, 66, 1487-1489.	0.7	3
194	Mutations to Cysteine Residues in the <i>Trypanosoma cruzi</i> B-Cell Superantigen Tc24 Diminish Susceptibility to IgM-Mediated Hydrolysis. <i>Journal of Parasitology</i> , 2017, 103, 579-583.	0.7	3
195	Response to "letter to the editor: "Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America". <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 673-675.	4.4	3
196	Mining the Metabolome for New and Innovative Chagas Disease Treatments. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 1-3.	8.7	3
197	Potency testing for a recombinant protein vaccine early in clinical development: Lessons from the <i>Schistosoma mansoni</i> Tetraspanin 2 vaccine. <i>Vaccine: X</i> , 2021, 8, 100100.	2.1	3
198	Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine. <i>Expert Review of Vaccines</i> , 2022, 21, 1185-1203.	4.4	3

#	ARTICLE	IF	CITATIONS
199	CspZ FH-Binding Sites as Epitopes Promote Antibody-Mediated Lyme Borreliae Clearance. <i>Infection and Immunity</i> , 2022, 90, .	2.2	3
200	Neglected Parasitic Infections and the Syndemic Anemia Vaccines for Africa. , 2019, , 75-85.		2
201	Role of the Extracellular Matrix and Cytoskeleton in the Regulation of Cyclins, Cyclindependent Kinase Inhibitors, and Anchorage-Dependent Growth. <i>Advances in Molecular and Cell Biology</i> , 1997, 24, 57-75.	0.1	1
202	A simple fluorescence-based assay for quantification of the Toll-Like Receptor agonist E6020 in vaccine formulations. <i>Vaccine</i> , 2017, 35, 1410-1416.	3.8	1
203	Inspiring women scientists in Honduras. <i>EBioMedicine</i> , 2019, 49, 21.	6.1	1
204	The Potential Economic Value of a Zika Vaccine for a Woman of Childbearing Age. <i>American Journal of Preventive Medicine</i> , 2020, 58, 370-377.	3.0	1
205	Diversity, Equity, and Inclusion in the Microbial Sciences—the Texas Perspective. <i>MBio</i> , 2021, 12, e0262021.	4.1	1
206	Reviewing a Decade of Outpatient Tropical Medicine in Houston, Texas. <i>American Journal of Tropical Medicine and Hygiene</i> , 2022, 106, 1049-1056.	1.4	1
207	Past, present, and future of Lyme disease vaccines: antigen engineering approaches and mechanistic insights. <i>Expert Review of Vaccines</i> , 2022, 21, 1405-1417.	4.4	1
208	Current Tropical Medicine Reports: A Path Forward to Highlight Research and Clinical Advances, New Trends and Innovations. <i>Current Tropical Medicine Reports</i> , 2014, 1, 1-2.	3.7	0
209	Global Health and Tropical Medicine in the Twenty-First Century: A Renewed Interest in the Understanding and the Control of Helminth Infections. <i>Current Tropical Medicine Reports</i> , 2015, 2, 238-240.	3.7	0
210	Human Hookworm Disease: Alternative Strategies to Achieve the Global Health Agenda for Elimination. <i>Current Treatment Options in Infectious Diseases</i> , 2017, 9, 223-229.	1.9	0
211	2257. <i>Journal of Clinical and Translational Science</i> , 2017, 1, 60-60.	0.6	0
212	I Never Thought I Had “Moral Courage,” until COVID-19 Happened. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 551-551.	1.4	0